Free tool
FAERS Monitor: Vyxeos
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 209401 or its brand name (Vyxeos, Cytarabine, Daunorubicin). Reports on generic versions are filed under their own applications.
Reports
2,431
Serious
2,136
88% of reports
Hospitalization
582
Death reported
825
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- febrile neutropenia528
- acute myeloid leukaemia313
- death244
- therapeutic product effect incomplete217
- pyrexia206
- acute myeloid leukaemia recurrent177
- rash152
- pneumonia151
- sepsis142
- off label use121
- cytopenia81
- disease progression80
- septic shock77
- drug ineffective76
- myelosuppression71
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2017 | 12 |
| 2018 | 77 |
| 2019 | 231 |
| 2020 | 183 |
| 2021 | 171 |
| 2022 | 346 |
| 2023 | 74 |
| 2024 | 471 |
| 2025 | 455 |
| 2026 | 411 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,728 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| acute myeloid leukaemia recurrentSignal | 177 | 777.3 | 670.0 | 125,221 |
| acute myeloid leukaemiaSignal | 313 | 177.3 | 159.7 | 53,635 |
| febrile neutropeniaSignal | 528 | 69.4 | 64.3 | 35,361 |
| cytopeniaSignal | 81 | 57.6 | 46.5 | 4,423 |
| therapeutic product effect incompleteSignal | 217 | 26.5 | 23.3 | 5,295 |
| myelosuppressionSignal | 71 | 17.1 | 13.6 | 1,059 |
| septic shockSignal | 77 | 15.3 | 12.3 | 1,018 |
| sepsisSignal | 142 | 11.0 | 9.4 | 1,290 |
| disease progressionSignal | 80 | 5.9 | 4.7 | 319 |
| pyrexiaSignal | 206 | 5.2 | 4.5 | 696 |
| pneumoniaSignal | 151 | 4.0 | 3.5 | 347 |
| rashSignal | 152 | 3.0 | 2.6 | 207 |
| deathSignal | 244 | 2.5 | 2.2 | 217 |
| off label use | 121 | 1.2 | 1.0 | 4 |
| drug ineffective | 76 | 0.5 | 0.4 | 40 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.